BioSig Expands Commercial Team in Two Strategic Regions
April 15 2021 - 11:45AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that it added two experienced
electrophysiology Regional Directors to lead commercial expansion
across Southeast and Central regions.
Mr. Robert Sandler, appointed to lead regional sales across
Texas, brings to the Company over 25 years of sales experience in
medical devices. Before joining BioSig, Mr. Sandler led regional
sales at CardioFocus, Inc. and Cardiva Medical, Inc. Earlier in his
career, he was responsible for the Dallas market at Biosense
Webster, a Johnson&Johnson company.
Mr. Timothy Jones, appointed to lead regional sales across
Florida, has over 20 years of medical equipment sales and sales
management experience. Previously, Mr. Jones led high-performing
commercial teams at CR Bard for Bard Electrophysiology and Bard
Access Systems. Most recently, Mr. Jones was employed by Boston
Scientific Corp., where he led regional sales for its Augmenix
division.
"We are very pleased to welcome Rob and Tim to our expanding
commercial team. Their combined industry expertise, proven track
record in medical device sales, and strong relationships in the
Texas and Florida electrophysiology markets will allow us to
accelerate our commercial sales in these strategically important
regions,” commented Kenneth L. Londoner, Chairman, and CEO of
BioSig Technologies, Inc.
With over 350 electrophysiology labs, Florida and Texas offer
some of the largest clinical footprints in the country. BioSig’s
PURE EPTM System is currently installed in eight medical
centers of excellence across the country, including Mayo Clinic
Florida Campus in Jacksonville, Florida, Texas Cardiac Arrhythmia
Institute at St. David’s Medical Center in Austin, TX, and Houston
Methodist Hospital in Houston, TX. The Company previously announced
that it completed commercial sales to St. David’s HealthCare and
Mayo Foundation for Medical Education and Research. The Company
expects to triple its customer base in 2021.
One in 18 Americans suffers from cardiac arrhythmia. Atrial
fibrillation is the most common arrhythmia type, affecting over 33
million people worldwide, including over 6 million in the U.S. The
number of people suffering from atrial fibrillation is expected to
reach 8-12 million by 2050.1 According to the Centers for Disease
Control and Prevention (CDC), atrial fibrillation causes more than
750,000 hospitalizations in the U.S. each year, resulting in
approximately $6 billion in healthcare spending annually2.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EPTM System is
a computerized system intended for acquiring, digitizing,
amplifying, filtering, measuring and calculating, displaying,
recording and storing of electrocardiographic and intracardiac
signals for patients undergoing electrophysiology (EP) procedures
in an EP laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
1 Top 10 Things You should Know About Heart Rhythm; Scripps
Health.
2 Managing Atrial Fibrillation; Lisa Eramom MA, Medical
Economics Journal, February 25, 2019, Volume 96, Issue 4
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Sep 2023 to Sep 2024